In this review, we outline the evolution of antibody therapies for gastric cancer, tracing their history from established targets like HER2 and VEGF through the introduction of immune checkpoint inhibitors (PD-1/PD-L1) to the recently emerging CLDN18.2, and we discuss future prospects, including next-generation modalities. This evidence concerns the gene CLDN18 and gastric cancer.